{"url":"https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-to-market-lanreotide-injection-12729295.html","title":"Cipla gets USFDA nod to market Lanreotide injection","description":"The company has received the final approval from the US Food and Drug Administration (USFDA) to market Lanreotide injection in multiple strengths, the Mumbai-based drug maker said in a statement.Cipla gets USFDA nod to market Lanreotide injection","content":"Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used to treat acromegaly and other conditions. The company has received the final approval from the US Food and Drug Administration (USFDA) to market Lanreotide injection in multiple strengths, the Mumbai-based drug maker said in a statement. The company's Lanreotide Injection is therapeutic equivalent generic version of Somatuline Depot Injection, it added. According to IQVIA (IMS Health), Somatuline Depot had sales of around USD 898 million in the US for the 12-month period ending March 2024. ","cleaned_content":"drug major cipla on wednesday said it has received approval from the us health regulator to market a generic medication used to treat acromegaly and other conditions the company has received the final approval from the us food and drug administration usfda to market lanreotide injection in multiple strengths the mumbai based drug maker said in a statement the companys lanreotide injection is therapeutic equivalent generic version of somatuline depot injection it added according to iqvia ims health somatuline depot had sales of around usd \u003cEIGHT_HUNDRED\u003e million in the us for the \u003cONE_TEN\u003e month period ending march \u003cTWO_THOUSAND\u003e","timestamp":"2024-05-22T12:24:00+05:30","market_timestamp":"2024-05-22T12:24:00+05:30","off_market_hours":false}